Heather Symecko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Heather Symecko has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Susan M. Domchek
Basser Center for BRCA, University of Pennsylvania, Philadelphia, PA, USA
5 shared publications - Adrianna L. Bartolomucci
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
3 shared publications - Akshaya V. Annapragada
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
3 shared publications - Beatriz Carvalho
Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
3 shared publications - Carolyn Hruban
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
3 shared publications - Christianne A. R. Lok
Department of Gynaecologic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands
3 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (8) , 102609
The impact of breast cancer polygenic risk score disclosure on decisional conflict around risk-reducing mastectomy in women with pathogenic BRCA1/2 variants
- 21 May 2026
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (8) , 102609
Open AccessThe impact of breast cancer polygenic risk score disclosure on decisional conflict around risk-reducing mastectomy in women with pathogenic BRCA1/2 variants
- Open Access
The Impact of Breast Cancer Polygenic Risk Score Disclosure on Decisional Conflict Around Risk-Reducing Mastectomy in BRCA1/2 Carriers
Purpose: Female BRCA1/2 carriers face high breast cancer risks and complex preventive decisions, which can generate decisional conflict. Polygenic Risk Scores (PRS) offer individualized risk estimates that may support decision-making. We examine whether PRS disclosure reduces decisional conflict in BRCA1/2 carriers and whether PRS magnitude interacts with numeracy and tolerance for ambiguity. Methods: Unaffected BRCA1/2 carriers ( N= 354) were assessed pre PRS disclosure (T0), one-week (T1), and six-months post-disclosure (T2). PRS were translated into 10-year and lifetime absolute breast cancer risk estimates. Mixed-effects models tested changes in decisional conflict, and regression/moderation analyses tested PRS effects and interactions with numeracy and tolerance for ambiguity. Results: Decisional conflict decreased significantly after PRS disclosure. Higher 10-year risk was associated with greater decisional conflict immediately after disclosure. Lifetime risk alone did not predict conflict. Tolerance for ambiguity moderated the effect of lifetime risk at T1: women with low/average tolerance experienced higher conflict with high PRS and lower conflict with low PRS. Numeracy, age, and family cancer history did not moderate PRS effects. Conclusion: Decisional conflict decreased post-PRS disclosure, with short-term responses influenced by tolerance for ambiguity. Findings suggest that PRS can complement standard BRCA1/2 genetic counseling and highlight the need for tailored risk communication.
Open AccessThe Impact of Breast Cancer Polygenic Risk Score Disclosure on Decisional Conflict Around Risk-Reducing Mastectomy in BRCA1/2 Carriers
Purpose: Female BRCA1/2 carriers face high breast cancer risks and complex preventive decisions, which can generate decisional conflict. Polygenic Risk Scores (PRS) offer individualized risk estimates that may support decision-making. We examine whether PRS disclosure reduces decisional conflict in BRCA1/2 carriers and whether PRS magnitude interacts with numeracy and tolerance for ambiguity. Methods: Unaffected BRCA1/2 carriers ( N= 354) were assessed pre PRS disclosure (T0), one-week (T1), and six-months post-disclosure (T2). PRS were translated into 10-year and lifetime absolute breast cancer risk estimates. Mixed-effects models tested changes in decisional conflict, and regression/moderation analyses tested PRS effects and interactions with numeracy and tolerance for ambiguity. Results: Decisional conflict decreased significantly after PRS disclosure. Higher 10-year risk was associated with greater decisional conflict immediately after disclosure. Lifetime risk alone did not predict conflict. Tolerance for ambiguity moderated the effect of lifetime risk at T1: women with low/average tolerance experienced higher conflict with high PRS and lower conflict with low PRS. Numeracy, age, and family cancer history did not moderate PRS effects. Conclusion: Decisional conflict decreased post-PRS disclosure, with short-term responses influenced by tolerance for ambiguity. Findings suggest that PRS can complement standard BRCA1/2 genetic counseling and highlight the need for tailored risk communication.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers
Supplementary Figure S1. Evaluation of screening model DELFI-Pro scores and comorbidities in individuals without cancer. Supplementary Figure S2. DELFI-Pro score evaluation in available clinical characteristics of patients with cancer. Supplementary Figure S3. Stability analysis across fold repeats and collection source. Supplementary Figure S4. Detection of ovarian cancer subtypes using DELFI-Pro screening model. Supplementary Figure S5. ROC analyses of asymptomatic individuals in the using screening or diagnostic models in the Discovery Cohort. Supplementary Figure S6. Performance of ichorCNA and median cfDNA fragment lengths in the Discovery Cohorts. Supplementary Figure S7. Detection of ovarian cancer subtypes using DELFI-Pro at high specificity. Supplementary Figure S8. Genome-wide fragmentation profiles are altered in patients in the Validation Cohort with ovarian cancer. Supplementary Figure S9. Analyses of chromosomal changes in Discovery and Validation cohorts. Supplementary Figure S10. Performance of DELFI-Pro for detection of ovarian cancer in the Validation Cohort. Supplementary Figure S11. Correlation of rank ordered DELFI-Pro scores for the Screening and Diagnostic models. Supplementary Figure S12. Assessment of DELFI-Pro in women with benign lesions. Supplementary Figure S13. Performance of DELFI-Pro for distinguishing ovarian cancer from benign masses. Supplementary Figure S14. Performance of DELFI-Pro for distinguishing ovarian cancer subtypes from benign masses. Supplementary Figure S15. Performance of DELFI-Pro for distinguishing ovarian cancer subtypes from benign masses in Validation Cohort. Supplementary Figure S16. Evaluation of overall tumor burden using the sum of reported lesion diameters. Supplementary Figure S17. Evaluation of CA1-25 and HE4 blood concentrations measured at different centers.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers
Supplementary Figure S1. Evaluation of screening model DELFI-Pro scores and comorbidities in individuals without cancer. Supplementary Figure S2. DELFI-Pro score evaluation in available clinical characteristics of patients with cancer. Supplementary Figure S3. Stability analysis across fold repeats and collection source. Supplementary Figure S4. Detection of ovarian cancer subtypes using DELFI-Pro screening model. Supplementary Figure S5. ROC analyses of asymptomatic individuals in the using screening or diagnostic models in the Discovery Cohort. Supplementary Figure S6. Performance of ichorCNA and median cfDNA fragment lengths in the Discovery Cohorts. Supplementary Figure S7. Detection of ovarian cancer subtypes using DELFI-Pro at high specificity. Supplementary Figure S8. Genome-wide fragmentation profiles are altered in patients in the Validation Cohort with ovarian cancer. Supplementary Figure S9. Analyses of chromosomal changes in Discovery and Validation cohorts. Supplementary Figure S10. Performance of DELFI-Pro for detection of ovarian cancer in the Validation Cohort. Supplementary Figure S11. Correlation of rank ordered DELFI-Pro scores for the Screening and Diagnostic models. Supplementary Figure S12. Assessment of DELFI-Pro in women with benign lesions. Supplementary Figure S13. Performance of DELFI-Pro for distinguishing ovarian cancer from benign masses. Supplementary Figure S14. Performance of DELFI-Pro for distinguishing ovarian cancer subtypes from benign masses. Supplementary Figure S15. Performance of DELFI-Pro for distinguishing ovarian cancer subtypes from benign masses in Validation Cohort. Supplementary Figure S16. Evaluation of overall tumor burden using the sum of reported lesion diameters. Supplementary Figure S17. Evaluation of CA1-25 and HE4 blood concentrations measured at different centers.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers
Supplementary Table S1. Summary of clinical information. Supplementary Table S2. Summary of sample characteristics. Supplementary Table S3. Summary of whole-genome sequencing and fragment analyses. Supplementary Table S4. Summary of protein analyses. Supplementary Table S5. Summary of machine learning models and scores. Supplementary Table S6. Summary of performance for ovarian cancer detection.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers
Supplementary Table S1. Summary of clinical information. Supplementary Table S2. Summary of sample characteristics. Supplementary Table S3. Summary of whole-genome sequencing and fragment analyses. Supplementary Table S4. Summary of protein analyses. Supplementary Table S5. Summary of machine learning models and scores. Supplementary Table S6. Summary of performance for ovarian cancer detection.
- Top Cited PapersOpen Access
- 30 September 2024
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (1) , 105-118
Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers
Ovarian cancer is a leading cause of death for women worldwide, in part due to ineffective screening methods. In this study, we used whole-genome cell-free DNA (cfDNA) fragmentome and protein biomarker [cancer antigen 125 (CA-125) and human epididymis protein 4 (HE4)] analyses to evaluate 591 women with ovarian cancer, with benign adnexal masses, or without ovarian lesions. Using a machine learning model with the combined features, we detected ovarian cancer with specificity >99% and sensitivities of 72%, 69%, 87%, and 100% for stages I to IV, respectively. At the same specificity, CA-125 alone detected 34%, 62%, 63%, and 100%, and HE4 alone detected 28%, 27%, 67%, and 100% of ovarian cancers for stages I to IV, respectively. Our approach differentiated benign masses from ovarian cancers with high accuracy (AUC = 0.88, 95% confidence interval, 0.83–0.92). These results were validated in an independent population. These findings show that integrated cfDNA fragmentome and protein analyses detect ovarian cancers with high performance, enabling a new accessible approach for noninvasive ovarian cancer screening and diagnostic evaluation. Significance: There is an unmet need for effective ovarian cancer screening and diagnostic approaches that enable earlier-stage cancer detection and increased overall survival. We have developed a high-performing accessible approach that evaluates cfDNA fragmentomes and protein biomarkers to detect ovarian cancer.
- 30 September 2024
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (1) , 105-118
Top Cited PapersOpen AccessEarly Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers
Ovarian cancer is a leading cause of death for women worldwide, in part due to ineffective screening methods. In this study, we used whole-genome cell-free DNA (cfDNA) fragmentome and protein biomarker [cancer antigen 125 (CA-125) and human epididymis protein 4 (HE4)] analyses to evaluate 591 women with ovarian cancer, with benign adnexal masses, or without ovarian lesions. Using a machine learning model with the combined features, we detected ovarian cancer with specificity >99% and sensitivities of 72%, 69%, 87%, and 100% for stages I to IV, respectively. At the same specificity, CA-125 alone detected 34%, 62%, 63%, and 100%, and HE4 alone detected 28%, 27%, 67%, and 100% of ovarian cancers for stages I to IV, respectively. Our approach differentiated benign masses from ovarian cancers with high accuracy (AUC = 0.88, 95% confidence interval, 0.83–0.92). These results were validated in an independent population. These findings show that integrated cfDNA fragmentome and protein analyses detect ovarian cancers with high performance, enabling a new accessible approach for noninvasive ovarian cancer screening and diagnostic evaluation. Significance: There is an unmet need for effective ovarian cancer screening and diagnostic approaches that enable earlier-stage cancer detection and increased overall survival. We have developed a high-performing accessible approach that evaluates cfDNA fragmentomes and protein biomarkers to detect ovarian cancer.